Prelude Net Income vs Stock Based Compensation Analysis

PRLD Stock

USD 0.76 0.01 1.33%

Prelude Therapeutics financial indicator trend analysis is much more than just breaking down Prelude Therapeutics prevalent accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Prelude Therapeutics is a good investment. Please check the relationship between Prelude Therapeutics Net Income and its Stock Based Compensation accounts. Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Prelude Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in bureau of economic analysis.

For information on how to trade Prelude Stock refer to our How to Trade Prelude Stock guide.

Net Income vs Stock Based Compensation

Net Income vs Stock Based Compensation Correlation Analysis

The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Prelude Therapeutics Net Income account and Stock Based Compensation. At this time, the significance of the direction appears to have pay attention.

The correlation between Prelude Therapeutics' Net Income and Stock Based Compensation is -0.98. Overlapping area represents the amount of variation of Net Income that can explain the historical movement of Stock Based Compensation in the same time period over historical financial statements of Prelude Therapeutics, assuming nothing else is changed. The correlation between historical values of Prelude Therapeutics' Net Income and Stock Based Compensation is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Net Income of Prelude Therapeutics are associated (or correlated) with its Stock Based Compensation. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Stock Based Compensation has no effect on the direction of Net Income i.e., Prelude Therapeutics' Net Income and Stock Based Compensation go up and down completely randomly.

Correlation Coefficient

-0.98

Relationship Direction	Negative
Relationship Strength	Significant

View All Relationships

Net Income

Net income is one of the most important fundamental items in finance. It plays a large role in Prelude Therapeutics financial statement analysis. It represents the amount of money remaining after all of Prelude Therapeutics operating expenses, interest, taxes and preferred stock dividends have been deducted from a company total revenue.

Stock Based Compensation

Compensation provided to employees in the form of equity or options to purchase company stock. This type of compensation is used to align the interests of employees and shareholders.

Most indicators from Prelude Therapeutics' fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Prelude Therapeutics current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Prelude Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in bureau of economic analysis.

For information on how to trade Prelude Stock refer to our How to Trade Prelude Stock guide.As of March 1, 2025, Selling General Administrative is expected to decline to about 18.9 M. In addition to that, Issuance Of Capital Stock is expected to decline to about 124.1 M

	2022	2023	2024	2025 (projected)
Reconciled Depreciation	1.3M	1.2M	1.4M	827.2K
Total Operating Expenses	123.5M	132.3M	152.1M	86.4M

Reconciled Depreciation Total Operating Expenses

Prelude Therapeutics fundamental ratios Correlations

	Total Assets	Other Current Liab	Total Current Liabilities	Total Stockholder Equity	Other Liab	Net Tangible Assets	Property Plant And Equipment Net	Net Debt	Retained Earnings	Accounts Payable	Cash	Non Current Assets Total	Cash And Short Term Investments	Common Stock Shares Outstanding	Non Current Liabilities Total	Other Stockholder Equity	Total Liab	Net Invested Capital	Property Plant And Equipment Gross	Total Current Assets	Non Current Liabilities Other	Net Working Capital	Property Plant Equipment	Short Long Term Debt Total	Other Current Assets	Short Term Debt
Total Assets		0.87	0.97	1.0	0.87	0.98	0.69	-0.26	-0.88	0.93	0.37	0.74	1.0	0.93	-0.8	0.88	-0.54	1.0	0.68	1.0	0.87	0.99	0.9	0.68	0.79	0.85
Other Current Liab	0.87		0.9	0.85	0.92	0.8	0.93	-0.04	-0.97	0.77	0.21	0.96	0.85	0.92	-0.64	0.97	-0.34	0.85	0.93	0.85	0.92	0.84	0.97	0.92	0.54	0.67
Total Current Liabilities	0.97	0.9		0.95	0.93	0.93	0.73	-0.09	-0.94	0.92	0.2	0.8	0.95	0.95	-0.73	0.92	-0.41	0.95	0.73	0.95	0.93	0.94	0.95	0.71	0.65	0.79
Total Stockholder Equity	1.0	0.85	0.95		0.85	0.99	0.65	-0.31	-0.85	0.93	0.41	0.7	1.0	0.9	-0.85	0.86	-0.61	1.0	0.64	1.0	0.85	1.0	0.88	0.64	0.81	0.87
Other Liab	0.87	0.92	0.93	0.85		0.82	0.82	0.17	-0.96	0.88	-0.03	0.88	0.85	0.87	-0.64	0.98	-0.36	0.85	0.82	0.85	1.0	0.84	0.98	0.8	0.61	0.69
Net Tangible Assets	0.98	0.8	0.93	0.99	0.82		0.58	-0.36	-0.81	0.94	0.45	0.64	0.99	0.85	-0.87	0.82	-0.66	0.99	0.57	0.99	0.82	0.99	0.85	0.57	0.85	0.91
Property Plant And Equipment Net	0.69	0.93	0.73	0.65	0.82	0.58		0.17	-0.89	0.52	0.01	0.99	0.65	0.85	-0.4	0.9	-0.13	0.65	1.0	0.65	0.82	0.64	0.85	1.0	0.33	0.36
Net Debt	-0.26	-0.04	-0.09	-0.31	0.17	-0.36	0.17		-0.06	-0.16	-0.98	0.17	-0.31	-0.07	0.48	0.1	0.55	-0.31	0.17	-0.31	0.17	-0.33	0.04	0.14	-0.42	-0.5
Retained Earnings	-0.88	-0.97	-0.94	-0.85	-0.96	-0.81	-0.89	-0.06		-0.81	-0.09	-0.93	-0.85	-0.93	0.63	-0.98	0.3	-0.85	-0.88	-0.85	-0.95	-0.84	-0.98	-0.87	-0.51	-0.66
Accounts Payable	0.93	0.77	0.92	0.93	0.88	0.94	0.52	-0.16	-0.81		0.25	0.61	0.94	0.77	-0.77	0.83	-0.55	0.93	0.52	0.94	0.88	0.94	0.88	0.5	0.83	0.91
Cash	0.37	0.21	0.2	0.41	-0.03	0.45	0.01	-0.98	-0.09	0.25		0.0	0.41	0.19	-0.55	0.05	-0.59	0.41	0.0	0.41	-0.03	0.43	0.11	0.03	0.48	0.58
Non Current Assets Total	0.74	0.96	0.8	0.7	0.88	0.64	0.99	0.17	-0.93	0.61	0.0		0.7	0.88	-0.46	0.94	-0.18	0.7	0.99	0.7	0.88	0.69	0.91	0.99	0.37	0.44
Cash And Short Term Investments	1.0	0.85	0.95	1.0	0.85	0.99	0.65	-0.31	-0.85	0.94	0.41	0.7		0.9	-0.83	0.85	-0.59	1.0	0.64	1.0	0.85	1.0	0.88	0.64	0.83	0.88
Common Stock Shares Outstanding	0.93	0.92	0.95	0.9	0.87	0.85	0.85	-0.07	-0.93	0.77	0.19	0.88	0.9		-0.65	0.91	-0.33	0.9	0.84	0.9	0.87	0.89	0.9	0.84	0.54	0.62
Non Current Liabilities Total	-0.8	-0.64	-0.73	-0.85	-0.64	-0.87	-0.4	0.48	0.63	-0.77	-0.55	-0.46	-0.83	-0.65		-0.66	0.91	-0.85	-0.39	-0.82	-0.64	-0.83	-0.66	-0.39	-0.72	-0.88
Other Stockholder Equity	0.88	0.97	0.92	0.86	0.98	0.82	0.9	0.1	-0.98	0.83	0.05	0.94	0.85	0.91	-0.66		-0.38	0.86	0.89	0.85	0.98	0.85	0.99	0.88	0.58	0.67
Total Liab	-0.54	-0.34	-0.41	-0.61	-0.36	-0.66	-0.13	0.55	0.3	-0.55	-0.59	-0.18	-0.59	-0.33	0.91	-0.38		-0.61	-0.13	-0.59	-0.36	-0.6	-0.37	-0.13	-0.68	-0.74
Net Invested Capital	1.0	0.85	0.95	1.0	0.85	0.99	0.65	-0.31	-0.85	0.93	0.41	0.7	1.0	0.9	-0.85	0.86	-0.61		0.64	1.0	0.85	1.0	0.88	0.64	0.81	0.87
Property Plant And Equipment Gross	0.68	0.93	0.73	0.64	0.82	0.57	1.0	0.17	-0.88	0.52	0.0	0.99	0.64	0.84	-0.39	0.89	-0.13	0.64		0.64	0.82	0.63	0.85	1.0	0.32	0.35
Total Current Assets	1.0	0.85	0.95	1.0	0.85	0.99	0.65	-0.31	-0.85	0.94	0.41	0.7	1.0	0.9	-0.82	0.85	-0.59	1.0	0.64		0.85	1.0	0.88	0.64	0.83	0.88
Non Current Liabilities Other	0.87	0.92	0.93	0.85	1.0	0.82	0.82	0.17	-0.95	0.88	-0.03	0.88	0.85	0.87	-0.64	0.98	-0.36	0.85	0.82	0.85		0.84	0.98	0.8	0.61	0.69
Net Working Capital	0.99	0.84	0.94	1.0	0.84	0.99	0.64	-0.33	-0.84	0.94	0.43	0.69	1.0	0.89	-0.83	0.85	-0.6	1.0	0.63	1.0	0.84		0.87	0.63	0.84	0.88
Property Plant Equipment	0.9	0.97	0.95	0.88	0.98	0.85	0.85	0.04	-0.98	0.88	0.11	0.91	0.88	0.9	-0.66	0.99	-0.37	0.88	0.85	0.88	0.98	0.87		0.83	0.62	0.74
Short Long Term Debt Total	0.68	0.92	0.71	0.64	0.8	0.57	1.0	0.14	-0.87	0.5	0.03	0.99	0.64	0.84	-0.39	0.88	-0.13	0.64	1.0	0.64	0.8	0.63	0.83		0.32	0.34
Other Current Assets	0.79	0.54	0.65	0.81	0.61	0.85	0.33	-0.42	-0.51	0.83	0.48	0.37	0.83	0.54	-0.72	0.58	-0.68	0.81	0.32	0.83	0.61	0.84	0.62	0.32		0.85
Short Term Debt	0.85	0.67	0.79	0.87	0.69	0.91	0.36	-0.5	-0.66	0.91	0.58	0.44	0.88	0.62	-0.88	0.67	-0.74	0.87	0.35	0.88	0.69	0.88	0.74	0.34	0.85

Click cells to compare fundamentals

Prelude Therapeutics Account Relationship Matchups

Prelude Therapeutics fundamental ratios Accounts

	2020	2021	2022	2023	2024	2025 (projected)
Total Assets	223.6M	305.1M	220.5M	277.7M	319.3M	195.3M
Other Current Liab	7.5M	7.9M	11.3M	15.8M	18.1M	19.0M
Total Current Liabilities	11.4M	19.2M	21.7M	21.8M	25.1M	14.9M
Total Stockholder Equity	212.2M	285.9M	195.4M	237.1M	272.7M	157.4M
Net Tangible Assets	(49.4M)	212.2M	285.9M	195.4M	224.8M	136.7M
Property Plant And Equipment Net	2.5M	5.6M	6.7M	37.7M	43.4M	45.6M
Net Debt	(218.3M)	(30.1M)	(28.8M)	(8.4M)	(9.7M)	(10.1M)
Retained Earnings	(107.4M)	(219.1M)	(334.6M)	(456.4M)	(410.8M)	(390.2M)
Accounts Payable	3.9M	7.8M	6.8M	4.6M	5.3M	4.8M
Cash	218.3M	31.8M	30.6M	25.3M	22.8M	45.4M
Non Current Assets Total	2.8M	10.0M	16.1M	42.1M	48.4M	50.8M
Cash And Short Term Investments	218.3M	291.2M	201.7M	232.9M	267.9M	179.4M
Common Stock Shares Outstanding	43.7M	47.6M	47.4M	60.4M	69.4M	48.3M
Liabilities And Stockholders Equity	223.6M	305.1M	220.5M	277.7M	319.3M	195.3M
Non Current Liabilities Total	32K	9.6M	3.4M	18.7M	16.9M	18.0M
Other Stockholder Equity	96.0M	505.7M	531.7M	693.3M	797.2M	837.1M
Total Liab	11.4M	19.2M	25.1M	40.6M	36.5M	27.6M
Net Invested Capital	212.2M	285.9M	195.4M	237.1M	272.7M	157.4M
Property Plant And Equipment Gross	2.5M	5.6M	6.7M	41.3M	47.5M	49.9M
Total Current Assets	220.8M	295.1M	204.4M	235.6M	270.9M	181.8M
Accumulated Other Comprehensive Income	(223.6M)	(711K)	(1.7M)	223K	256.5K	269.3K
Non Current Liabilities Other	5K	32K	3.4M	3.3M	3.8M	4.0M
Net Working Capital	209.4M	275.9M	182.7M	213.8M	245.8M	166.9M
Property Plant Equipment	1.6M	2.5M	5.6M	6.7M	7.7M	8.1M
Other Current Assets	5M	7.8M	2.7M	2.7M	3.1M	4.3M

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

CRM	Salesforce
C	Citigroup
GM	General Motors

When determining whether Prelude Therapeutics is a strong investment it is important to analyze Prelude Therapeutics' competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Prelude Therapeutics' future performance. For an informed investment choice regarding Prelude Stock, refer to the following important reports:

How To Invest In Prelude

Details

Is Prelude Stock a good investment?

Details

What is Prelude Therapeutics' Net Worth?

Details

Largest Biotechnology Companies

View

Largest Pharmaceuticals, Biotechnology & Life Sciences Companies

View

Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Prelude Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in bureau of economic analysis.

For information on how to trade Prelude Stock refer to our How to Trade Prelude Stock guide.

You can also try the Financial Widgets module to easily integrated Macroaxis content with over 30 different plug-and-play financial widgets.

Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Prelude Therapeutics. If investors know Prelude will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Prelude Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.

Earnings Share

(1.77)

Revenue Per Share

0.04

Return On Assets

(0.39)

Return On Equity

(0.67)

The market value of Prelude Therapeutics is measured differently than its book value, which is the value of Prelude that is recorded on the company's balance sheet. Investors also form their own opinion of Prelude Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Prelude Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Prelude Therapeutics' market value can be influenced by many factors that don't directly affect Prelude Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.

Please note, there is a significant difference between Prelude Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Prelude Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Prelude Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

Prelude Net Income vs Stock Based Compensation Analysis

Net Income vs Stock Based Compensation

Net Income vs Stock Based Compensation Correlation Analysis

Correlation Coefficient

Net Income

Stock Based Compensation

Prelude Therapeutics fundamental ratios Correlations

Prelude Therapeutics Account Relationship Matchups

High Positive Relationship

High Negative Relationship

Prelude Therapeutics fundamental ratios Accounts

Also Currently Popular

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Total Stockholder Equity	+ 1.0	Total Assets
Cash And Short Term Investments	+ 1.0	Total Assets
Net Invested Capital	+ 1.0	Total Assets
Total Current Assets	+ 1.0	Total Assets
Cash And Short Term Investments	+ 1.0	Total Stockholder Equity
Net Invested Capital	+ 1.0	Total Stockholder Equity

Property Plant Equipment	- 0.98	Retained Earnings
Other Stockholder Equity	- 0.98	Retained Earnings
Cash	- 0.98	Net Debt
Retained Earnings	- 0.97	Other Current Liab
Retained Earnings	- 0.96	Other Liab
Non Current Liabilities Other	- 0.95	Retained Earnings